Branden Moriarity has in the past year accelerated hope for patients with solid-tumor cancers, says Steph Kennelly, program manager for the Minneapolis-based Center for Genome Engineering, part of the University of Minnesota Medical School. He has helped bring Minnesota’s first multi-disease tumor-infiltrating lymphocytes (TIL) therapy clinic trial from idea to implementation. The Un-TIL It’s Cured program offers a new path to patients with ovarian, GI, breast, lung, liver, sarcoma, pancreatic, and other hard-to-treat cancers. “Branden collaborates closely with patient advocates, nonprofit partners, and colleagues to ensure the science remains human-centered and accessible,” Kennelly says. “His efforts strengthen Minnesota’s role as a national leader in innovative, compassionate cancer care.”